Knight Therapeutics Revitalizes ONICIT® for Patients in LATAM
Knight Therapeutics Refreshes ONICIT® Launch in LATAM Markets
Knight Therapeutics Inc., a leading specialty pharmaceutical company in the Americas, has revealed its plans to fully take over the commercial responsibilities for ONICIT® IV (palonosetron) in Brazil and Mexico. This initiative is being executed through its strong partnerships with United Medical Ltd. and Grupo Biotoscana de Especialidad S.A. de C.V. This revitalization marks a significant step in Knight’s commitment to providing effective treatments for patients battling the effects of chemotherapy.
Strategic Partnership Expansion
The renewed focus on ONICIT® is not a spontaneous decision; rather, it follows a strategic partnership initiated in May 2022. During this collaboration, Knight Therapeutics and Helsinn Healthcare SA secured an exclusive agreement for the distribution of various oncology treatments across several key markets, including Canada, Brazil, Argentina, Uruguay, and Paraguay. In January 2025, they further expanded this relationship, adding ONICIT® to their robust lineup of products in Mexico and Brazil.
The Importance of ONICIT®
ONICIT® is recognized for its effectiveness in preventing nausea and vomiting related to chemotherapy, a common and distressing side effect for cancer patients. This solution is approved not only for preventing acute nausea induced by both moderately and highly emetogenic chemotherapy cycles but also for managing postoperative nausea and vomiting (PONV) in adults. In Brazil, ONICIT® even has pediatric indications, addressing the needs of younger patients undergoing similar treatments.
Enhancing Patient Care
Samira Sakhia, President and CEO of Knight, expressed pride in the company’s ability to deliver treatments like ONICIT® that improve the quality of life for patients. “ONICIT® complements our oncology offering and allows us to leverage our existing medical and commercial infrastructure to benefit more patients,” she stated. This strategic enhancement is vital for supporting healthcare providers in managing patients’ chemotherapy-related challenges effectively.
What Sets ONICIT® Apart?
ONICIT® stands out as a second-generation 5-HT3 receptor antagonist, boasting a superior affinity for the receptor compared to older variants. This means a single administration of ONICIT® before chemotherapy can prevent nausea over an extended period, simplifying treatment protocols for both healthcare providers and patients. Its effectiveness has been validated in clinical studies, demonstrating strong outcomes in both the acute and delayed phases following chemotherapy.
About Knight Therapeutics Inc.
Headquartered in Montreal, Canada, Knight Therapeutics Inc. excels in acquiring, in-licensing, and marketing pharmaceutical products across Canada and Latin America. The company operates through its subsidiaries, including United Medical and Biotoscana Farma, broadening its reach and impact.
Investor Relations
For inquiries, investors can reach out to Knight Therapeutics Inc. at the contact details below:
Samira Sakhia
President & Chief Executive Officer
Phone: 514.484.4483
Email: IR@knighttx.com
Arvind Utchanah
Chief Financial Officer
Phone: +598.2626.2344
Email: IR@knighttx.com
Frequently Asked Questions
What is ONICIT® used for?
ONICIT® is primarily used to prevent nausea and vomiting associated with chemotherapy and to manage postoperative nausea and vomiting in patients.
How does ONICIT® work?
ONICIT® acts as a 5-HT3 receptor antagonist, blocking the action of serotonin at these receptors, which plays a key role in inducing nausea and vomiting.
Why is the relaunch significant for Knight Therapeutics?
The relaunch signifies Knight's commitment to enhancing patient care in Latin America by providing effective treatments for chemotherapy-related symptoms.
What markets are included in the ONICIT® relaunch?
The ONICIT® relaunch focuses primarily on Brazil and Mexico, tapping into existing partnerships for enhanced distribution.
Who can benefit from ONICIT®?
Both adult and pediatric cancer patients undergoing chemotherapy can benefit from ONICIT®, especially those experiencing acute nausea and vomiting.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.